Patient profile, treatment exposure, and disease burden in myasthenia gravis: a baseline cross-sectional analysis of the MG-China cohort
The Lancet Regional Health - Western Pacific · 2026-11 · 76 · 102035
DOI: 10.1016/j.lanwpc.2026.102035 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift The Lancet Regional Health - Western Pacific, 2026-11. Verfasst von Ting Chang und 39 weiteren Autor:innen. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Large-scale, prospectively designed studies are needed to characterize clinical profiles, treatment exposure, and disease burden in myasthenia gravis (MG) cohorts in China. We aimed to describe these features using baseline data from a multicenter cohort (MG-China).
Methods
We conducted a baseline cross-sectional analysis of MG-China, an ongoing prospective registry comprising a tertiary-hospital, referral-based, quota-enriched cohort. Between September 2024 and June 2025, 1199 patients with MG were enrolled at 32 tertiary hospitals across China. Baseline and retrospectively reconstructed historical medical data were collected, including demographics, clinical assessments (Quantitative Myasthenia Gravis [QMG) Score, Myasthenia Gravis Activities of Daily Living [MG-ADL) score), and treatment regimes. This study is registered with ClinicalTrials.gov ( NCT06700616 ).
Findings
Very late-onset patients (≥65 years; n = 284 [23.7%]) showed a higher burden of comorbidity and significantly greater residual disease burden, as reflected by higher QMG and MG-ADL scores and lower EQ-5D utility values. Refractory MG (n = 267 [22.3%]) showed a longer disease duration and consistently greater disease burden across all clinical measurements. Targeted biologics exposure was more frequent among patients with refractory MG and those with very late-onset age.
Interpretation
Among participants enrolled in this tertiary-hospital referral-based cohort, clinical characteristics and disease burden differed across age-at-onset and disease severity subgroups. Very late-onset and refractory MG were associated with greater residual disease burden at enrollment. Prospective follow-up of this cohort will be important for identifying factors independently associated with disease burden and for clarifying how treatment selection and timing relate to long-term clinical outcomes. Funding: AstraZeneca Global R&D (China) Co., Ltd .
Zitieren
APA
Chang, T., Yang, C., Ruan, Z., Gao, F., Jiang, Q., Tan, S., Yue, Y., Zhang, W., Huang, W., Zhong, D., Zhang, W., Maimaiti, M., Yuan, B., Jiang, Y., Gu, H., Yang, K., Li, H., Wu, T., Ma, X., …, & Zhang, W. (2026). Patient profile, treatment exposure, and disease burden in myasthenia gravis: a baseline cross-sectional analysis of the MG-China cohort. The Lancet Regional Health - Western Pacific, 76, 102035. https://doi.org/10.1016/j.lanwpc.2026.102035
Vancouver
Chang T, Yang C, Ruan Z, Gao F, Jiang Q, Tan S, et al. Patient profile, treatment exposure, and disease burden in myasthenia gravis: a baseline cross-sectional analysis of the MG-China cohort. The Lancet Regional Health - Western Pacific. 2026;76:102035. doi:10.1016/j.lanwpc.2026.102035
BibTeX
@article{Chang2026,
author = {Chang, Ting and Yang, Chunsheng and Ruan, Zhe and Gao, Feng and Jiang, Qilong and Tan, Song and Yue, Yaoxian and Zhang, Weihe and Huang, Wen and Zhong, Di and Zhang, Wei and Maimaiti, Mayinuer and Yuan, Baoshi and Jiang, Yong and Gu, Hongqiu and Yang, Kaixuan and Li, Huanhuan and Wu, Ti and Ma, Xiaoguang and Bai, Lu and Wang, Yanyan and Yuan, Dong and Guo, Qin and Wang, Huabing and Qi, Guoyan and Meng, Xia and Shi, Fu-Dong and Shi, Fu-Dong and Wang, Huabing and Chang, Ting and Qi, Guoyan and Gao, Feng and Yang, Chunsheng and Jiang, Qilong and Tan, Song and Yue, Yaoxian and Zhang, Weihe and Huang, Wen and Zhong, Di and Zhang, Wei},
title = {Patient profile, treatment exposure, and disease burden in myasthenia gravis: a baseline cross-sectional analysis of the MG-China cohort},
journal = {The Lancet Regional Health - Western Pacific},
year = {2026},
volume = {76},
pages = {102035},
doi = {10.1016/j.lanwpc.2026.102035}
}
EUVIMED